Ben Locwin

His expertise spans early-phase pharmaceutical drug development through post-market commercialization and scale-up of therapeutic assets across a wide range of Therapeutic Areas, including oncology, neurology, endocrinology, immunology, cardiology, and others. Ben also has held leadership roles in Quality and Regulatory functions for biopharmaceutical and medical device companies, helping to bring six novel medicines through successful FDA approval, in addition to cutting-edge combination medical devices and diagnostic technologies.

His patient-centric work has included partnering with clinics and hospitals to improve healthcare treatment outcomes, including within surgical centers to analyze and reduce post-surgical complication rates, and to help establish frameworks for Patient Reported Outcomes (PROs). He has worked with industry investors on the ‘next big things’ and has been an invited keynote speaker and chairman for several industry conferences. He has served an appointment as an expert media contact for the American Association of Pharmaceutical Scientists, and has been featured in the Wall Street Journal, Forbes, USA Today, the Associated Press, and other top-tier media.